Abstract. Shortly after extracorporeal shock wave lithotripsy (ESWL) was introduced as a promising new treatment modality for gallstone disease, a randomized controlled study was performed to assess the cost-effectiveness of ESWL compared to open cholecystectomy, the gold standard. During the performance of this study it was found that during a 3-year intake period only 8.3% (37 of 448) of the patients could be entered into the trial. Three factors were identified that hampered patient accrual: (1) restricted eligibility for ESWL (and thus for the study), which could not have been predicted on the data provided in the literature; (2) the introduction of laparoscopic cholecystectomy; and (3) strong patient preference, inhibiting randomization. All three mechanisms could not have been predicted during the design phase of the study. It is concluded that it is not always feasible to conduct a randomized study in surgery due to unforeseen circumstances. Entering patients into surgical trials is difficult in quickly evolving fields of surgery, such as the management of gallstone disease. Acquiring informed consent is also difficult when treatment characteristics are divergent. A randomized controlled study on the effects of laparoscopic cholecystectomy will therefore probably never be performed.
Gallstone disease is an important clinical problem in Western countries and traditionally considered a surgical problem. It is generally agreed that open cholecystectomy is the standard therapy for symptomatic gallstones [1, 2] . Still, much effort is put into the development of alternative, preferably noninvasive, treatment modalities for gallstone disease [3] . One of these recently developed, noninvasive, treatment modalities is extracorporeal shock wave lithotripsy (ESWL). The initial results of ESWL to treat gallbladder stones were promising [3] [4] [5] .
Because of the possible positive clinical and economic consequences of ESWL, we started a study on the effects of this new technique and its cost-effectiveness [6] . We chose a randomized controlled design because randomized studies are considered to provide the most reliable information for proper evaluation of new techniques [7] [8] [9] [10] [11] [12] [13] [14] . Moreover, in this way discussions could be avoided, similar to the ones that developed after the general Correspondence to: P.W. Plaisier, M.D.
adoption of ESWL of kidney stones: This treatment modality almost completely displaced open surgery without a randomized study ever being performed [15] [16] [17] .
During the performance of our study, several problems were encountered in acquiring adequate patient accrual. In this paper we describe the difficulties we met in this area.
Patients and Methods
To ensure optimal patient accrual for our randomized study, a surgical outpatient clinic solely for gallstone patients was started. Over a 3-year intake period, 596 patients visited this outpatient clinic.
All patients were analyzed according to protocol. A history was obtained and a physical examination performed for all patients. Using the Roma Working Group definition [18] , patients were diagnosed as either symptomatic or asymptomatic. Asymptomatic patients were excluded from further analysis and did not receive therapy. With symptomatic patients the various therapeutic options were discussed, and these patients underwent further analysis: laboratory tests and radiologic examination.
Laboratory tests consisted of liver function tests for screening on common bile duct stones. Radiologic examination comprised ultrasonography (US) and oral cholecystography (OCG). OCG was not performed if the patient refused ESWL as a therapeutic option or if a previous US examination already excluded the patient from ESWL (Table 1) .
At the end of analysis, all eligible patients were informed about the study and were asked to consent to be randomized. When informed consent was given, therapy was randomly assigned, and self-administered health questionnaires and interviews were undertaken at 0, 3, 6, 12, 18, and 24 months. If patients did not want to participate in the study, they received the therapy of their choice.
The study protocol was approved by the Medical Ethics Corn- There were 12 patients who discontinued analysis, and 96 patients were not symptomatic ( Table 2) . Of 488 patients, potentially randomizable, 310 (63.5%) were excluded because they did not meet the entry criteria (Table 1) . Another 141 patients (28.9%) were excluded because they denied random assignment of therapy. Hence 37 patients (18, 12, and 7 for each year, respectively) consented to enter the study, which is 6.2% of the total number of analyzed patients and 7.6% of the patients potentially randomizable. There were 18 patients randomized for cholecystectomy and 19 for ESWL.
Discussion
There is unanimous agreement that new treatment techniques should be introduced in a manner that allows proper evaluation [7] . Although randomized studies have specific problems, they are considered to provide the most reliable information for such evaluation [7] [8] [9] [10] [11] [12] [13] [14] 19] . The mechanism of allocating patients to different treatment schemes by randomization is accepted almost without question now [10] .
New surgical techniques are considered more difficult to evaluate than new drugs [16, 20] . In fact, most clinical research in surgery relies on comparison with historical or contemporary nonrandom controls [11] . One of the most striking examples of [15] . This development consequently led to much discussion, as no randomized study was ever performed [16, 17] . When ESWL was introduced for the disintegration of gallbladder stones, it was therefore suggested that the proper assessment of the role of ESWL should be dealt with in the context of a randomized trial [3] .
During the performance of our study, only a few patients could be randomized. It should be noted here that despite this poor patient entry it was decided to continue the study because (1) interim analysis showed some interesting points; (2) five other hospitals decided to participate in the study; and (3) a large number of nonrandomized patients were entered into the study. However, because this point is not the subject of this manuscript it is not discussed here.
Poor patient entry was due to three mechanisms that could not have been predicted when the study was designed: (1) Contrary to the data in the literature, eligibility for ESWL was found to be limited. (2) Yet another alternative treatment of gallbladder stones was introduced during the performance of our study. (3) Strong patient preference for one of the two treatment arms was encountered that inhibited randomization.
Restricted Eligibility for ESWL
Partial applicability had already been reported by Sackmann and coworkers [4] , but this point was not considered a major obstacle for our study, as we had reasons to assume that our eligibility rate would be higher than that reported by the Munich group, because our entry criteria (Table 1) were much wider than those of the Munich group, especially with regard to the maximum number of stones (10 versus 3), and another research group had reported a randomization rate of 57.1% in a trial comparable to ours [21] . Moreover, even at Sackmann et al.'s eligibility rate of 28%, accrual of 160 patients--estimated to be necessary to detect any clinically relevant differences in the two treatment options--was considered to be easily achieved within 3 years at our referral rate of approximately 200 patients per year.
Introduction of Another Alternative Treatment
Shortly after our study was started, a new variant of classic cholecystectomy was introduced: laparoscopic cholecystectomy [22, 23] . Compared to the "open" technique, laparoscopic chole- cystectomy is reported to have several advantages. It is accompanied by less morbidity and mortality and consequently by a reduction in duration of hospitalization, the time to return to full activity, and the need for analgesic drugs. Also for cosmetic reasons, laparoscopic cholecystectomy is more attractive. Laparoscopic cholecystectomy is now considered the gold standard [24] even though this technique has not been studied in the context of a randomized trial.
Strong Patient Preference
Many mechanisms can lead to strong patient preference. Two mechanisms limited accrual in our case: adherence to new technologies and the divergent character of the two treatment arms. The lay press probably reinforced these two mechanisms.
Adherence to New Technologies. Emotional adherence to a new technology is considered a major obstacle for randomization, and it may become insurmountable if it has become known to the general public [13] . We encountered this phenomenon twice: at the beginning of the study when patients specifically chose ESWL, and at a later stage of the trial when patients specifically opted for laparoscopic cholecystectomy.
Divergent Character of the Two Treatment Arms. Strong patient
preference also occurs when the treatment modalities studied are divergent [25, 26] . ESWL and cholecystectomy have indeed different characteristics (Table 3) ; and because the outcomes of these characteristics were so clear to many patients they specifically opted for a certain treatment modality and simply rejected random assignment. It has been recognized that comparing treatment regimens with divergent characteristics is difficult [27] : Only 2% of eligible patients are recruited in breast cancer trials in the United States [28] ; and in a trial comparing mastectomy and conservation surgery in Great Britain fewer than half of the eligible patients could be recruited [29] . Recently, some of the large trials comparing percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass graft (CBAG) have also had to stop patient intake without having recruited the desired number of patients [30] .
In the field of gallstone management , a trial comparing laparoscopic cholecystectomy and the "mini-cholecystectomy" suffered from a high withdrawel rate after randomization, and this trial was eventually stopped because of ditficult patient recruitment [31] . The only alternative to overcome this particular problem clearly would have been to randomize patients without their informed consent, analogous to the European Carotid Surgery Trial [32] .
Role of the Lay Press. The role of the lay press in hampering patient accrual has been recognized [29] . In our study the lay press played an important role in promoting patient preference. In some popular magazines the success of ESWL and of laparoscopic cholecystectomy were exaggerated, and the possibility of failure and complications were underestimated or not mentioned at all, which promoted the patient preference to a large extent. As a consequence, the universal adoption of laparoscopic cholecystectomy has been patient-driven [33, 34] as a result of media exposure [35] .
Conclusions
Our data confirm that proper information on the feasibility of a trial is not always available before the study is started [35] . Our data also confirm that it is not always feasible to conduct a randomized study because of inadequate patient accrual [9] .
Furthermore, we confirmed that acquiring informed consent is much more difficult if treatment characteristics are divergent and that comparing different forms of therapy in a randomized study is hazardous in the quickly evolving field of surgery, such as the management of gallstone disease. It is therefore equally true that a prospective controlled study on the effects of laparoscopic cholecystectomy cannot be performed [7, 36] . In such cases alternatives to randomized studies must be used [8, 13, 26, 37] .
R~sum~
Peu apr6s l'introduction de la lithotritie par ondes de choc extracorporelles (LOCE) comme modalit6 th6rapeutique nouvelle dans la lithiase biliaire, nous avons commenc6 une 6tude randomis6e pour 6valuer le cofits de la LOCE compar~e /t la choldcystectomie traditionnelle, le "gold standard". Pendant cette 6tude s'dtalant sur une p6riode de trois ans, il n'a 6t6 possible, cependant, d'inclure que 8.3% seulement (37/488) des patients 6ventuellement 61igibles. Trois facteurs pouvant emp~cher le recrutement ont pu 6tre identifi6s. Premibrement, un nombre limit6 de patients 61igibles pour la LOCE (et donc pour l'6tude), fait impr6visible selon les donndes de la litt6rature, deuxi6me-ment, 1'introduction de Ia chol6cystectomie par coelioscopie et son retentissement sur l'aspect th6rapeutique de la lithiase, et troisi6mement, la pr6f6rence du patient, refusant la randomisation clans un bon nombre de cas. On conclue qu'il n'est pas toujours aussi facile de conduire une 6tude randomis6e en chirurgie, en raison des circonstances impr6vues. Entrer des patients dans un essai est tr6s difficile dans des domaines qui 6voluent vite, tel que le traitement de la lithiase biliaire. Obtenir le consentement 6clair6 est 6galement difficile lorsque les modalitds th6rapeutiques sont tr6s divergentes. I1 est probable que la rdalisation d'une 6tude randomis6e et contr616e sur les effets de la chol6cystectomie coelioscopique ne verra jamais le jour.
Resumen A1 poco tiempo de la introducci6n de la litotricia extracorp6rea (LEC) como un promisoria y novel modalidad terap6utica para la enfermedad litifisica biliar, se realiz6 un estudio randomizado para evaluar la efectividad en cuanto a costo en comparaci6n con la colecistectomfa abierta, que es el "patr6n oro". Se encontr6 que en los 3 afios del perfodo de ingreso de pacientes al estudio, s61o 8.3% (36 = 7/448) de los pacientes pudieron ser ingresados, habi6ndose identificado tres que interfirieron con el reclutamiento. Primero, la restringida elegibilidad para LEC (y pot consiguiente para el estudio), lo cual no era predecible con base en la informaci6n de la literatura. Segundo, la introducci6n de la colecistectomfa laparosc6pica. Tercero, una fuerte preferencia por parte del paciente, lo cual inhibfa la randomizaci6n. Ninguno de estos mecanismos podfa ser previsto durante la fase de disefio del estudio. La conclusidn es que no siempre es factible conducir estudios randomizados en el campo de la cirug~a, debido a circunstancias imprevistas. Ingresar pacientes a ensayos cl[nicos en cirugfa es diffcil cuando se trata de campos de r~ipida evoluci6n, como lo es del manejo de la colelitiasis. Tambi6n es diffcil lograr el consentimiento informado cuando las caracterfsticas de las formas de tratamiento son muy divergentes. Es por ello, que posiblemente nunca se har~ un estudio randomizado sobre los efectos de la colecistectom[a laparosc6pica.
